{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:15:50Z","timestamp":1790997350915,"version":"4.1.0"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009009","name":"Heilongjiang University of Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.cca.2026.120874","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T16:46:41Z","timestamp":1769705201000},"page":"120874","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Tumor microenvironment and biomarker innovation in ovarian cancer: mechanistic insights into immune evasion, angiogenesis, and therapeutic resistance"],"prefix":"10.1016","volume":"584","author":[{"given":"Ye","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cca.2026.120874_bb0005","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1186\/s12967-025-06508-0","article-title":"Role of tumor microenvironment in ovarian cancer metastasis and clinical advancements","volume":"23","author":"Wang","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.cca.2026.120874_bb0010","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3389\/fcell.2020.00758","article-title":"Tumor microenvironment in ovarian cancer: function and therapeutic strategy","volume":"8","author":"Yang","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"11","key":"10.1016\/j.cca.2026.120874_bb0015","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1158\/1055-9965.EPI-12-0646","article-title":"Biomarkers for screening, diagnosis, and monitoring of ovarian cancer","volume":"21","author":"Kobayashi","year":"2012","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"issue":"5","key":"10.1016\/j.cca.2026.120874_bb0020","doi-asserted-by":"crossref","first-page":"831","DOI":"10.32604\/or.2024.031006","article-title":"Deciphering resistance mechanisms and novel strategies to overcome drug resistance in ovarian cancer: a comprehensive review","volume":"32","author":"Alemzadeh","year":"2024","journal-title":"Oncol. Res."},{"key":"10.1016\/j.cca.2026.120874_bb0025","doi-asserted-by":"crossref","unstructured":"Blanc-Durand, F., L. Clemence Wei Xian, and D.S. Tan, Targeting the immune microenvironment for ovarian cancer therapy. Front. Immunol., 2023. 14: p. 1328651.","DOI":"10.3389\/fimmu.2023.1328651"},{"issue":"4","key":"10.1016\/j.cca.2026.120874_bb0030","first-page":"443","article-title":"Research hotspot and application status of immune evasion mechanism in ovarian Cancer","volume":"11","author":"Zhang","year":"2023","journal-title":"J. Biosci. Med."},{"key":"10.1016\/j.cca.2026.120874_bb0035","doi-asserted-by":"crossref","unstructured":"Mendoza-Martinez, A., et al., Modeling the Tumor Microenvironment of Ovarian Cancer: The Application of Self-Assembling Biomaterials. Cancers 2021, 13, 5745. 2021, s Note: MDPI stays neutral with regard to jurisdictional claims in published\u00a0\u2026.","DOI":"10.3390\/cancers13225745"},{"issue":"7","key":"10.1016\/j.cca.2026.120874_bb0040","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.3390\/curroncol31070283","article-title":"The complex tumor microenvironment in ovarian cancer: therapeutic challenges and opportunities","volume":"31","author":"Garlisi","year":"2024","journal-title":"Curr. Oncol."},{"issue":"6","key":"10.1016\/j.cca.2026.120874_bb0045","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/mp.55.6.348","article-title":"Angiogenesis in epithelian ovarian cancer","volume":"55","author":"Bamberger","year":"2002","journal-title":"Mol. Pathol."},{"issue":"8","key":"10.1016\/j.cca.2026.120874_bb0050","doi-asserted-by":"crossref","first-page":"15885","DOI":"10.3390\/ijms140815885","article-title":"Angiogenesis-related pathways in the pathogenesis of ovarian cancer","volume":"14","author":"Gavalas","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cca.2026.120874_bb0055","doi-asserted-by":"crossref","first-page":"1147717","DOI":"10.3389\/fphar.2023.1147717","article-title":"Anti-angiogenic therapy in ovarian cancer: current understandings and prospects of precision medicine","volume":"14","author":"Mei","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cca.2026.120874_bb0060","unstructured":"Tucker, K., MDedge ObGyn."},{"key":"10.1016\/j.cca.2026.120874_bb0065","doi-asserted-by":"crossref","unstructured":"Yang, L., et al., Molecular mechanisms of platinum\u2011based chemotherapy resistance in ovarian cancer. Oncol. Rep., 2022. 47(4): p. 1\u201311.","DOI":"10.3892\/or.2022.8293"},{"key":"10.1016\/j.cca.2026.120874_bb0070","first-page":"1","article-title":"Mechanisms of chemoresistance in human ovarian cancer at a glance","volume":"2","author":"Liu","year":"2012","journal-title":"Gynecol. Obstetr."},{"issue":"9","key":"10.1016\/j.cca.2026.120874_bb0075","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3390\/cells13090786","article-title":"Deciphering the molecular mechanisms behind drug resistance in ovarian cancer to unlock efficient treatment options","volume":"13","author":"Nunes","year":"2024","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.cca.2026.120874_bb0080","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1159\/000539642","article-title":"Role of Cancer side population stem cells in ovarian Cancer angiogenesis","volume":"33","author":"Pan","year":"2024","journal-title":"Med. Princ. Pract."},{"issue":"3","key":"10.1016\/j.cca.2026.120874_bb0085","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3390\/diagnostics11030465","article-title":"New predictive biomarkers for ovarian cancer","volume":"11","author":"Atallah","year":"2021","journal-title":"Diagnostics"},{"issue":"1","key":"10.1016\/j.cca.2026.120874_bb0090","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/proteomes12010008","article-title":"Biomarkers in ovarian cancer: toward personalized medicine","volume":"12","author":"L\u00f3pez-Portugu\u00e9s","year":"2024","journal-title":"Proteomes"},{"issue":"19","key":"10.1016\/j.cca.2026.120874_bb0095","doi-asserted-by":"crossref","first-page":"12041","DOI":"10.3390\/ijms231912041","article-title":"Molecular biomarkers for the early detection of ovarian cancer","volume":"23","author":"Zhang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.cca.2026.120874_bb0100","doi-asserted-by":"crossref","first-page":"81","DOI":"10.31557\/apjcb.2024.9.1.81-85","article-title":"Biomarkers for early detection of ovarian cancer: a review","volume":"9","author":"Bindu","year":"2024","journal-title":"Asian Pacific J. Cancer Biol."},{"key":"10.1016\/j.cca.2026.120874_bb0105","doi-asserted-by":"crossref","first-page":"1667464","DOI":"10.3389\/fimmu.2025.1667464","article-title":"Decoding immune low-response states in ovarian cancer: insights from single-cell and spatial transcriptomics for precision immunotherapy","volume":"16","author":"Yan","year":"2025","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.cca.2026.120874_bb0110","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.trecan.2024.09.001","article-title":"Crosstalk of T cells within the ovarian cancer microenvironment","volume":"10","author":"Chap","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.cca.2026.120874_bb0115","doi-asserted-by":"crossref","first-page":"1631226","DOI":"10.3389\/fimmu.2025.1631226","article-title":"Immunosuppressive mechanisms and therapeutic targeting of regulatory T cells in ovarian cancer","volume":"16","author":"Li","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cca.2026.120874_bb0120","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41419-025-07557-5","article-title":"Immune evasion mechanisms in early-stage I high-grade serous ovarian carcinoma: insights into regulatory T-cell dynamics","volume":"16","author":"Mikulak","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cca.2026.120874_bb0125","series-title":"Seminars in Oncology","article-title":"CTLA-4 blockade in ovarian cancer immunotherapy: Mechanisms and clinical strategies","author":"Hsu","year":"2025"},{"key":"10.1016\/j.cca.2026.120874_bb0130","doi-asserted-by":"crossref","first-page":"1384121","DOI":"10.3389\/fimmu.2024.1384121","article-title":"Further knowledge and developments in resistance mechanisms to immune checkpoint inhibitors","volume":"15","author":"Berland","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cca.2026.120874_bb0135","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-022-01282-8","article-title":"Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets","volume":"15","author":"Tie","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cca.2026.120874_bb0140","doi-asserted-by":"crossref","first-page":"155948","DOI":"10.1016\/j.prp.2025.155948","article-title":"Tumor-derived extracellular vesicles: hijacking T cell function through exhaustion","volume":"29","author":"Guo","year":"2025","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.cca.2026.120874_bb0145","doi-asserted-by":"crossref","first-page":"1161848","DOI":"10.3389\/fimmu.2023.1161848","article-title":"Deciphering the roles of myeloid derived suppressor cells in viral oncogenesis","volume":"14","author":"Glover","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2026.120874_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.577869","article-title":"Immunotherapy for ovarian cancer: adjuvant, combination, and neoadjuvant","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2026.120874_bb0155","doi-asserted-by":"crossref","unstructured":"Hormaty, S., et al., A Review on Biomarker\u2010Enhanced Machine Learning for Early Diagnosis and Outcome Prediction in Ovarian Cancer Management. Cancer Med., 2025. 14(17): p. e71224.","DOI":"10.1002\/cam4.71224"},{"issue":"5","key":"10.1016\/j.cca.2026.120874_bb0160","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cca.2026.120874_bb0165","doi-asserted-by":"crossref","first-page":"1543096","DOI":"10.3389\/fimmu.2025.1543096","article-title":"The role of macrophage polarization in ovarian cancer: from molecular mechanism to therapeutic potentials","volume":"16","author":"Xu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2026.120874_bb0170","series-title":"Blocking IL-4 May Improve Immunotherapy Response in Ovarian Cancer","author":"Fuerst","year":"2025"},{"key":"10.1016\/j.cca.2026.120874_bb0175","doi-asserted-by":"crossref","first-page":"1677839","DOI":"10.3389\/fimmu.2025.1677839","article-title":"Advance in therapies targeting tumor-associated macrophages in ovarian cancer","volume":"16","author":"Li","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cca.2026.120874_bb0180","doi-asserted-by":"crossref","first-page":"5694","DOI":"10.1038\/s41467-024-49916-4","article-title":"Single-cell resolution characterization of myeloid-derived cell states with implication in cancer outcome","volume":"15","author":"Guimar\u00e3es","year":"2024","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.cca.2026.120874_bb0185","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70248","article-title":"Spatial genomics uncovers cytokines promoting ovarian tumor heterogeneity and immunotherapy resistance","volume":"15","author":"Mollaoglu","year":"2025","journal-title":"Clin. Transl. Med."},{"issue":"26","key":"10.1016\/j.cca.2026.120874_bb0190","doi-asserted-by":"crossref","first-page":"7492","DOI":"10.1016\/j.cell.2024.10.006","article-title":"Ovarian cancer-derived IL-4 promotes immunotherapy resistance","volume":"187","author":"Mollaoglu","year":"2024","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.cca.2026.120874_bb0195","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.cca.2026.120874_bb0200","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","article-title":"Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches","volume":"10","author":"Tufail","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"20","key":"10.1016\/j.cca.2026.120874_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e38888","article-title":"Examining the evidence for immune checkpoint therapy in high-grade serous ovarian cancer","volume":"10","author":"Connor","year":"2024","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.cca.2026.120874_bb0210","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41392-024-01826-z","article-title":"Development of pharmacological immunoregulatory anticancer therapeutics: current mechanistic studies and clinical opportunities","volume":"9","author":"Yin","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cca.2026.120874_bb0215","doi-asserted-by":"crossref","first-page":"1426050","DOI":"10.3389\/fimmu.2024.1426050","article-title":"The role of B7-H4 in ovarian cancer immunotherapy: current status, challenges, and perspectives","volume":"15","author":"Zhou","year":"2024","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.cca.2026.120874_bb0220","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1665460","article-title":"Tumor cell expression of B7-H4 correlates with higher frequencies of tumor-infiltrating APCs and higher CXCL17 expression in human epithelial ovarian cancer","volume":"8","author":"MacGregor","year":"2019","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.cca.2026.120874_bb0225","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/immuno5030023","article-title":"Integrative transcriptomic Meta-analysis reveals risk signatures and immune infiltration patterns in high-grade serous ovarian Cancer","volume":"5","author":"Morales-Su\u00e1rez","year":"2025","journal-title":"Immuno"},{"issue":"1","key":"10.1016\/j.cca.2026.120874_bb0230","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41419-022-04510-8","article-title":"Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion","volume":"13","author":"Tian","year":"2022","journal-title":"Cell Death Dis."},{"issue":"8","key":"10.1016\/j.cca.2026.120874_bb0235","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.3390\/biomedicines12081806","article-title":"Extracellular vesicles in ovarian Cancer: from Chemoresistance mediators to therapeutic vectors","volume":"12","author":"Muttiah","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.cca.2026.120874_bb0240","doi-asserted-by":"crossref","first-page":"1601266","DOI":"10.3389\/fimmu.2025.1601266","article-title":"Cancer cell-derived extracellular vesicles: a potential target for overcoming tumor immunotherapy resistance and immune evasion strategies","volume":"16","author":"Ahn","year":"2025","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.cca.2026.120874_bb0245","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1038\/s12276-024-01340-w","article-title":"Influencing immunity: role of extracellular vesicles in tumor immune checkpoint dynamics","volume":"56","author":"Ye","year":"2024","journal-title":"Exp. Mol. Med."},{"issue":"1","key":"10.1016\/j.cca.2026.120874_bb0250","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s13048-025-01864-3","article-title":"Vascular endothelial generating factor pathway in ovarian cancer","volume":"18","author":"Zhao","year":"2025","journal-title":"J. Ovarian Res."},{"issue":"6","key":"10.1016\/j.cca.2026.120874_bb0255","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.0959-9673.2004.00404.x","article-title":"Vascular endothelial growth factor reduces mural cell coverage of endothelial cells and induces sprouting rather than luminal division in an HT1080 tumor angiogenesis model","volume":"85","author":"Fujimoto","year":"2004","journal-title":"Int. J. Exp. Pathol."},{"issue":"1","key":"10.1016\/j.cca.2026.120874_bb0260","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cca.2026.120874_bb0265","doi-asserted-by":"crossref","first-page":"1589841","DOI":"10.3389\/fbioe.2025.1589841","article-title":"Bevacizumab in ovarian cancer therapy: current advances, clinical challenges, and emerging strategies","volume":"13","author":"Zhang","year":"2025","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"1","key":"10.1016\/j.cca.2026.120874_bb0270","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1038\/s41467-024-45974-w","article-title":"Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group","volume":"15","author":"Freyer","year":"2024","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.cca.2026.120874_bb0275","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/s41416-021-01330-z","article-title":"Vascular normalization as the stepping stone into tumor microenvironment transformation","volume":"125","author":"Magnussen","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"13","key":"10.1016\/j.cca.2026.120874_bb0280","doi-asserted-by":"crossref","first-page":"6934","DOI":"10.3390\/ijms23136934","article-title":"Novel drugs with high efficacy against tumor angiogenesis","volume":"23","author":"Qi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.cca.2026.120874_bb0285","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3390\/ijms25020921","article-title":"The inhibition of vessel co-option as an emerging strategy for cancer therapy","volume":"25","author":"Carrera-Aguado","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.cca.2026.120874_bb0290","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3892\/ol.2023.14043","article-title":"Advance in vasculogenic mimicry in ovarian cancer","volume":"26","author":"Tian","year":"2023","journal-title":"Oncol. Lett."},{"issue":"6","key":"10.1016\/j.cca.2026.120874_bb0295","doi-asserted-by":"crossref","first-page":"291","DOI":"10.5483\/BMBRep.2020.53.6.060","article-title":"Angiogenesis and vasculogenic mimicry as therapeutic targets in ovarian cancer","volume":"53","author":"Lim","year":"2020","journal-title":"BMB Rep."},{"issue":"2","key":"10.1016\/j.cca.2026.120874_bb0300","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10456-024-09907-x","article-title":"Group XIV C-type lectins: emerging targets in tumor angiogenesis","volume":"27","author":"Yee","year":"2024","journal-title":"Angiogenesis"},{"issue":"4","key":"10.1016\/j.cca.2026.120874_bb0305","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1111\/jcmm.14133","article-title":"PARP inhibitors in ovarian cancer: sensitivity prediction and resistance mechanisms","volume":"23","author":"Jiang","year":"2019","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"10.1016\/j.cca.2026.120874_bb0310","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.cca.2026.120874_bb0315","doi-asserted-by":"crossref","first-page":"1598279","DOI":"10.3389\/fphar.2025.1598279","article-title":"Research progress on ferroptosis and PARP inhibitors in ovarian cancer: action mechanisms and resistance mechanisms","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10.1016\/j.cca.2026.120874_bb0320","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.7150\/jca.82233","article-title":"CRTC2 promotes paclitaxel resistance by inducing autophagy in ovarian cancer in part via the PI3K-AKT signaling axis","volume":"14","author":"Ou","year":"2023","journal-title":"J. Cancer"},{"issue":"1","key":"10.1016\/j.cca.2026.120874_bb0325","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3390\/curroncol31010015","article-title":"Prediction of chemoresistance how preclinical data could help to modify therapeutic strategy in high-grade serous ovarian cancer","volume":"31","author":"Wilczy\u0144ski","year":"2023","journal-title":"Curr. Oncol."},{"issue":"1","key":"10.1016\/j.cca.2026.120874_bb0330","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/s13046-024-03239-w","article-title":"Pathogenic mitochondrial DNA variants are associated with response to anti-VEGF therapy in ovarian cancer PDX models","volume":"43","author":"Boso","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.cca.2026.120874_bb0335","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1136\/ijgc-2023-004995","article-title":"Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Lorusso","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.cca.2026.120874_bb0340","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41698-024-00640-8","article-title":"Spatial tumor immune microenvironment phenotypes in ovarian cancer","volume":"8","author":"Mateiou","year":"2024","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.cca.2026.120874_bb0345","doi-asserted-by":"crossref","first-page":"1582738","DOI":"10.3389\/fonc.2025.1582738","article-title":"SLFN11: a pancancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance","volume":"15","author":"Zhou","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cca.2026.120874_bb0350","doi-asserted-by":"crossref","unstructured":"Ratz, L., S. Baek, and S. Panier, Revisiting Genomic Instability, Tumor Microenvironment and Immune Response in High-Grade Serous Ovarian Cancer. Geburtshilfe und Frauenheilkunde, 2025. 85: p. 694 - 709.","DOI":"10.1055\/a-2613-0489"},{"issue":"1","key":"10.1016\/j.cca.2026.120874_bb0355","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41392-024-01828-x","article-title":"Notch signaling pathway in cancer: from mechanistic insights to targeted therapies","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cca.2026.120874_bb0360","doi-asserted-by":"crossref","first-page":"1567524","DOI":"10.3389\/fimmu.2025.1567524","article-title":"The role of notch signaling pathway in cancer: mechanistic insights, therapeutic potential, and clinical progress","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cca.2026.120874_bb0365","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13048-025-01589-3","article-title":"Identification of exosome-related SERPINB1 as a novel predictor for tumor immune microenvironment and clinical outcomes in ovarian cancer","volume":"18","author":"Gu","year":"2025","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.cca.2026.120874_bb0370","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.678747","article-title":"Identification of CXCL10-relevant tumor microenvironment characterization and clinical outcome in ovarian cancer","volume":"12","author":"Jin","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.cca.2026.120874_bb0375","doi-asserted-by":"crossref","first-page":"1412328","DOI":"10.3389\/fimmu.2024.1412328","article-title":"Recent advances in understanding the immune microenvironment in ovarian cancer","volume":"15","author":"Chen","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2026.120874_bb0380","first-page":"1193","article-title":"Systemic inflammatory biomarkers as a predictive markers for ovarian Cancer","author":"Kurniadi","year":"2025","journal-title":"Int. J. Womens Health"},{"issue":"9","key":"10.1016\/j.cca.2026.120874_bb0385","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.3390\/ijms21093125","article-title":"The ovarian cancer tumor immune microenvironment (TIME) as target for therapy: a focus on innate immunity cells as therapeutic effectors","volume":"21","author":"Baci","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.cca.2026.120874_bb0390","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3892\/or.2022.8313","article-title":"Tumor microenvironment manipulates chemoresistance in ovarian cancer","volume":"47","author":"Zhang","year":"2022","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.cca.2026.120874_bb0395","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13048-024-01471-8","article-title":"Targeted proteomics of plasma extracellular vesicles uncovers MUC1 as combinatorial biomarker for the early detection of high-grade serous ovarian cancer","volume":"17","author":"Cooper","year":"2024","journal-title":"J. Ovarian Res."},{"issue":"13","key":"10.1016\/j.cca.2026.120874_bb0400","doi-asserted-by":"crossref","first-page":"7070","DOI":"10.3390\/ijms25137070","article-title":"The impact of neoadjuvant chemotherapy on ovarian cancer tumor microenvironment: a systematic review of the literature","volume":"25","author":"Spagnol","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.cca.2026.120874_bb0405","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ygyno.2020.09.045","article-title":"Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: a dynamic landscape","volume":"160","author":"Blanc-Durand","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.cca.2026.120874_bb0410","series-title":"Tumor Microenvironment Complexity and its Therapeutic Implications","first-page":"1543814","author":"Dos Anjos","year":"2025"},{"issue":"1","key":"10.1016\/j.cca.2026.120874_bb0415","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s12957-025-03957-1","article-title":"ctDNA methylation profiling reveals NBL1 as a promising biomarker for early ovarian cancer screening","volume":"23","author":"Zhou","year":"2025","journal-title":"World J. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.cca.2026.120874_bb0420","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1186\/s12967-025-06643-8","article-title":"Unraveling the role of M2 TAMs in ovarian cancer dynamics: a systematic review","volume":"23","author":"Wang","year":"2025","journal-title":"J. Transl. Med."},{"issue":"3\u20134","key":"10.1016\/j.cca.2026.120874_bb0425","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1177\/03936155231186163","article-title":"Immune checkpoints as potential theragnostic biomarkers for epithelial ovarian cancer","volume":"38","author":"Habel","year":"2023","journal-title":"Int. J. Biol. Markers"},{"key":"10.1016\/j.cca.2026.120874_bb0430","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.matbio.2023.02.004","article-title":"Extracellular matrix in high-grade serous ovarian cancer: advances in understanding of carcinogenesis and cancer biology","volume":"118","author":"Brown","year":"2023","journal-title":"Matrix Biol."},{"issue":"6","key":"10.1016\/j.cca.2026.120874_bb0435","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3390\/biomedicines9060693","article-title":"Ovarian cancer: biomarkers and targeted therapy","volume":"9","author":"Radu","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.cca.2026.120874_bb0440","series-title":"Ovarian cancer Biomarkers: Moving Forward in Early Detection","first-page":"355","author":"Bonif\u00e1cio","year":"2020"},{"issue":"23","key":"10.1016\/j.cca.2026.120874_bb0445","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.2217\/fon.15.251","article-title":"Current state of biomarkers in ovarian cancer prognosis","volume":"11","author":"Au","year":"2015","journal-title":"Future Oncol."},{"issue":"3","key":"10.1016\/j.cca.2026.120874_bb0450","first-page":"399","article-title":"Circulating noncoding RNAs in recurrent and metastatic ovarian cancer","volume":"2","author":"Schwarzenbach","year":"2019","journal-title":"Cancer Drug Resistance"},{"key":"10.1016\/j.cca.2026.120874_bb0455","doi-asserted-by":"crossref","unstructured":"Cammarata, G., et al., Extracellular vesicles-ceRNAs as ovarian cancer biomarkers: looking into circRNA-miRNA\u2013mRNA code. Cancers, 2022. 14(14): p. 3404.","DOI":"10.3390\/cancers14143404"},{"issue":"1","key":"10.1016\/j.cca.2026.120874_bb0460","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s11658-021-00284-7","article-title":"CircRNAs as potent biomarkers in ovarian cancer: a systematic scoping review","volume":"26","author":"Foruzandeh","year":"2021","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.cca.2026.120874_bb0465","doi-asserted-by":"crossref","unstructured":"Zhu, Z., et al., Exosome\u2010Associated Gene Signature for Predicting the Prognosis of Ovarian Cancer Patients. J. Immunol. Res., 2023. 2023(1): p. 8727884.","DOI":"10.1155\/2023\/8727884"},{"issue":"40","key":"10.1016\/j.cca.2026.120874_bb0470","doi-asserted-by":"crossref","first-page":"36614","DOI":"10.1021\/acsomega.3c02837","article-title":"Unlocking exosome-based theragnostic signatures: deciphering secrets of ovarian cancer metastasis","volume":"8","author":"Mukherjee","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.cca.2026.120874_bb0475","doi-asserted-by":"crossref","first-page":"1228235","DOI":"10.3389\/fimmu.2024.1228235","article-title":"An exosome-derived lncRNA signature identified by machine learning associated with prognosis and biomarkers for immunotherapy in ovarian cancer","volume":"15","author":"Cui","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2026.120874_bb0480","doi-asserted-by":"crossref","unstructured":"Wang, Z.-B., et al., Spatial Profiling of the Metabolism-Immune Axis in Ovarian Cancer. Frontiers in Pharmacology. 16: p. 1672020.","DOI":"10.3389\/fphar.2025.1672020"},{"issue":"6","key":"10.1016\/j.cca.2026.120874_bb0485","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1158\/2159-8290.CD-24-1366","article-title":"Multimodal spatial profiling reveals immune suppression and microenvironment remodeling in fallopian tube precursors to high-grade serous ovarian carcinoma","volume":"15","author":"Kader","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cca.2026.120874_bb0490","doi-asserted-by":"crossref","first-page":"1288027","DOI":"10.3389\/fimmu.2023.1288027","article-title":"Unveiling the novel immune and molecular signatures of ovarian cancer: insights and innovations from single-cell sequencing","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.cca.2026.120874_bb0495","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3390\/cells14100681","article-title":"Identification of prognostic biomarkers of ovarian high-grade serous carcinoma: a preliminary study using spatial transcriptome analysis and multispectral imaging","volume":"14","author":"Kang","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.cca.2026.120874_bb0500","article-title":"Identification of tumor microenvironment-related prognostic biomarkers for ovarian serous Cancer 3-year mortality using targeted maximum likelihood estimation: a TCGA data mining study","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Genet."},{"issue":"3","key":"10.1016\/j.cca.2026.120874_bb0505","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/jmp6030020","article-title":"The future of cancer diagnosis and treatment: unlocking the power of biomarkers and personalized molecular-targeted therapies","volume":"6","author":"Molla","year":"2025","journal-title":"Journal of Molecular Pathology"},{"issue":"1","key":"10.1016\/j.cca.2026.120874_bb0510","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13048-021-00814-z","article-title":"Plasma-derived exosomal miR-4732-5p is a promising noninvasive diagnostic biomarker for epithelial ovarian cancer","volume":"14","author":"Liu","year":"2021","journal-title":"J. Ovarian Res."},{"issue":"1","key":"10.1016\/j.cca.2026.120874_bb0515","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3390\/cimb44010021","article-title":"Circulating exosomal miR-1290 for diagnosis of epithelial ovarian cancer","volume":"44","author":"Jeon","year":"2022","journal-title":"Curr. Issues Mol. Biol."},{"key":"10.1016\/j.cca.2026.120874_bb0520","doi-asserted-by":"crossref","unstructured":"Yen, Y.-T., et al., Tumor extracellular vesicle surface Protein\u2013mRNA integration assay for early detection of epithelial ovarian cancer. EBioMedicine, 2025. 119.","DOI":"10.1016\/j.ebiom.2025.105884"},{"issue":"1","key":"10.1016\/j.cca.2026.120874_bb0525","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12575-021-00161-9","article-title":"Immune-related long noncoding RNA constructs a prognostic signature of ovarian cancer","volume":"23","author":"Sun","year":"2021","journal-title":"Biol. Procedures Online"},{"issue":"4","key":"10.1016\/j.cca.2026.120874_bb0530","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3390\/biomedicines13040877","article-title":"Integrative Bioinformatic analysis of cellular senescence genes in ovarian Cancer: molecular subtyping, prognostic risk stratification, and Chemoresistance prediction","volume":"13","author":"Li","year":"2025","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.cca.2026.120874_bb0535","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12916-024-03826-w","article-title":"Promising new drugs and therapeutic approaches for treatment of ovarian cancer targeting the hallmarks of cancer","volume":"23","author":"Hillmann","year":"2025","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.cca.2026.120874_bb0540","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13046-023-02779-x","article-title":"Anti-VEGF therapy selects for clones resistant to glucose starvation in ovarian cancer xenografts","volume":"42","author":"Boso","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.cca.2026.120874_bb0545","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41392-023-01419-2","article-title":"Patient-derived xenograft models in cancer therapy: technologies and applications","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126000562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126000562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T19:58:29Z","timestamp":1771963109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898126000562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":109,"alternative-id":["S0009898126000562"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2026.120874","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor microenvironment and biomarker innovation in ovarian cancer: mechanistic insights into immune evasion, angiogenesis, and therapeutic resistance","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2026.120874","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"120874"}}